Bearish Sentiment: Biomea Fusion Scraps Equity Offering, Delays Study Data
Biomea Fusion stock falls after ending a public securities offering and revising clinical data timelines for its obesity trial.
Stocks · News reference
Biomea Fusion Terminates Proposed Public Offering Of Securities Due To Market Conditions
Biomea Fusion, Inc. ("Biomea" or the "Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced that it has terminated its proposed public offering of securities, previously
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Biomea Fusion shares are trading lower after the company announced the termination of its proposed public offering of securities.
Why Worthington Enterprises Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
Worthington Enterprises surged 15.9% premarket after beating Q1 EPS and sales estimates; Wheeler REIT led gainers, while Jaguar Health and Biomea fell.